Published in Vaccine Weekly, June 8th, 2011
"Although the prognosis of chronic and smoldering-type ATL is relatively good, that of patients with acute-or lymphoma-type ATL still remains extremely poor. Zidovudine/IFN-a therapy seems to be promising, although...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly